Literature DB >> 24214876

IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation.

Xiaoran Wu1, Yi Tan, Qiao Xing, Shengdian Wang.   

Abstract

Graft-versus-host disease (GVHD) is a prevalent and potential complication of hematopoietic stem cell transplantation. An animal model, xenogeneic GVHD (X-GVHD), that mimics accurately the clinical presentation of GVHD would provide a tool for investigating the mechanism involved in disease pathogenesis. Murine models indicated that inhibiting IL-21 signaling was a good therapy to reduce GVHD by impairing T cell functions. We sought to investigate the effect of exogenous human IL-21 on the process of X-GVHD. In this study, human IL-21 was expressed by hydrodynamic gene delivery in BALB/c-Rag2⁻/⁻ IL-2RΓc⁻/⁻ (BRG) immunodeficient mice which were intravenously transplanted human peripheral blood mononuclear cells (hPBMCs). We found that human IL-21 exacerbated X-GVHD and resulted in rapid fatality. As early as 6 days after hPBMCs transplanted to BRG mice, a marked expansion of human CD19⁺ B cells, but not T cells, was observed in spleen of IL-21-treated mice. Compared with control group, IL-21 induced robust immunoglobulin secretion, which was accompanied by increased accumulation of CD19CD38(high) plasma cells in spleen. In addition, we demonstrated that B-cell depletion was able to ameliorate X-GVHD. These results are the first to find in vivo expansion and differentiation of human B cells in response to IL-21, and reveal a correlation between the expansion of B cells and the exacerbation of xenogeneic GVHD. Our findings show evidence of the involvement of B cells in X-GVHD and may have implications in the treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24214876      PMCID: PMC4875455          DOI: 10.1007/s13238-013-3088-8

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  31 in total

1.  Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Kristen E Stevenson; Haesook T Kim; Whitney S Washel; Nazmim S Bhuiya; Corey S Cutler; Edwin P Alyea; Vincent T Ho; Robert J Soiffer; Joseph H Antin; Jerome Ritz
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

2.  Humanized mice as a preclinical tool for infectious disease and biomedical research.

Authors:  Leonard D Shultz; Michael A Brehm; Sina Bavari; Dale L Greiner
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

Review 3.  Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation.

Authors:  Warren J Leonard; Rosanne Spolski
Journal:  Nat Rev Immunol       Date:  2005-09       Impact factor: 53.106

4.  IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells.

Authors:  Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

5.  A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.

Authors:  Y V van Oosterhout; L van Emst; A V Schattenberg; W J Tax; D J Ruiter; H Spits; F M Nagengast; R Masereeuw; S Evers; T de Witte; F W Preijers
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

Review 6.  Graft-versus-host disease.

Authors:  Warren D Shlomchik
Journal:  Nat Rev Immunol       Date:  2007-05       Impact factor: 53.106

7.  Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease.

Authors:  Klaus Warnatz; Axel Denz; Ruth Dräger; Moritz Braun; Christoph Groth; Guido Wolff-Vorbeck; Hermann Eibel; Michael Schlesier; Hans Hartmut Peter
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

8.  Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations.

Authors:  Chunyan Zhang; Ivan Todorov; Zhifang Zhang; Yinping Liu; Fouad Kandeel; Stephen Forman; Samuel Strober; Defu Zeng
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 9.  The role of IL-21 in regulating B-cell function in health and disease.

Authors:  Rachel Ettinger; Stefan Kuchen; Peter E Lipsky
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

Review 10.  Advances in graft-versus-host disease biology and therapy.

Authors:  Bruce R Blazar; William J Murphy; Mehrdad Abedi
Journal:  Nat Rev Immunol       Date:  2012-05-11       Impact factor: 53.106

View more
  5 in total

1.  Therapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD.

Authors:  Anne-Kathrin Hechinger; Benjamin A H Smith; Ryan Flynn; Kathrin Hanke; Cameron McDonald-Hyman; Patricia A Taylor; Dietmar Pfeifer; Björn Hackanson; Franziska Leonhardt; Gabriele Prinz; Heide Dierbach; Annette Schmitt-Graeff; Jiri Kovarik; Bruce R Blazar; Robert Zeiser
Journal:  Blood       Date:  2014-10-28       Impact factor: 22.113

2.  Behçet's disease physiopathology: a contemporary review.

Authors:  Mohamad J Zeidan; David Saadoun; Marlene Garrido; David Klatzmann; Adrien Six; Patrice Cacoub
Journal:  Auto Immun Highlights       Date:  2016-02-12

3.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

4.  Evaluation of Serum Interleukin-21 and HLA-C1 Polymorphism in Pediatrician Hematopoietic Stem Cell Transplantation for Early Diagnosis of Acute Graft-Versus-Host Disease

Authors:  N Sehati; P Kokhaei; A Motevalizade Ardekani; R Tootoonchian; F Pak
Journal:  Iran Biomed J       Date:  2017-06-19

5.  Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation.

Authors:  Aurélie Tormo; Fatemeh Khodayarian; Yun Cui; Edouard Al-Chami; Reem Kanjarawi; Beatriz Noé; Huijie Wang; Moutih Rafei
Journal:  J Hematol Oncol       Date:  2017-06-14       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.